AbbVie’s Skyrizi Wins FDA Approval for Psoriatic Arthritis

The FDA has approved AbbVie’s Skyrizi (risankizumab-rzaa) for treating adults with psoriatic arthritis, an inflammatory disease that afflicts an estimated 30 percent of psoriasis sufferers.

The drug was previously FDA-approved in April 2019 for treating moderate-to-severe plaque psoriasis in adults.

The approval was supported by two phase 3 studies showing Skyrizi significantly improved symptoms, such as swollen, tender and painful joints after 24 weeks of treatments.

Skyrizi works by blocking the inflammatory IL-23 cytokine which has been linked with several chronic immune-mediated diseases. The drug was previously FDA-approved in April 2019 for treating moderate-to-severe plaque psoriasis in adults.

Part of a partnership between Boehringer Ingelheim and AbbVie, Skyrizi is being developed and commercialised by AbbVie worldwide.

January 25, 2022

https://www.fdanews.com/